UPDATE 1-FDA names drugmakers likely blocking access to drug samples

May 17 (Reuters) - The U.S. Food and Drug Administration on Thursday listed drugmakers, including Celgene Corp, Mylan NV, Gilead Sciences and Novartis AG , who the regulator says are potentially blocking access to samples of their drugs to delay generic competition.